Clinical studies found that advanced Parkinson's disease patients gained a daily average of 1.7 - 2.9 hours of relatively good functioning, with the combined therapy. A progressive neurological disorder, Parkinson's disease affects one and one-half million Americans. Symptoms include uncontrollable tremors or shaking, slowness of movements, stiffness, poor balance and a shuffling walk. There is no cure for Parkinson's disease.
Current therapies focus on symptom control.
Tasmar is an important new option for the treatment of Parkinson's disease. Patients enjoy fewer tremors, improved mobility and overall improvement in conducting daily activities. These patients also experienced improved motor function. In addition, these patients experienced a significant improvement in their symptoms, overall, as measured by the investigator's global assessment of change. By inhibiting the action of the COMT enzyme, Tasmar, a COMT inhibitor, provides smoother and more sustained levels of levodopa to the brain which it is believed translates into more consistent and effective symptom relief for people with Parkinson's disease.